Head-to-head clinical trial data inside

Ozempic vs Zepbound: Which Is Better in 2026?

SURMOUNT-5 head-to-head trial, real April 2026 pricing, insurance reality, and who should choose which — all in one place.

By The RX Index Editorial Team · Last verified April 3, 2026 · FDA labels checked · Pricing verified from official manufacturer pages · Affiliate disclosure

Some links on this page are affiliate links. If you click through and take action, we may earn a commission at no extra cost to you. Affiliate relationships do not influence our editorial conclusions.

Full comparison →Who should choose →Trial evidence →When Ozempic wins →2026 pricing →Insurance →Side effects →Switching →Wrong comparison? →FAQ →

The key finding, upfront

For most adults comparing these two for weight loss, Zepbound is the stronger medication. In the first head-to-head clinical trial (SURMOUNT-5, New England Journal of Medicine, 2025), tirzepatide produced 20.2% average body weight loss versus 13.7% for semaglutide over 72 weeks — 47% more relative weight loss.^¹ Zepbound is also FDA-approved for weight loss. Ozempic is not.^²

But if you have type 2 diabetes — especially with heart disease or kidney concerns — Ozempic may be the smarter medical choice. Its cardiovascular and kidney protections are FDA-labeled and proven in dedicated trials.^² Zepbound can’t make those claims yet.

Check Your Insurance Coverage for Ozempic or Zepbound on Ro →

Free coverage checker · PA handling · Licensed clinicians · Separate membership fee applies

Ozempic vs Zepbound — Which fits your goal? Two injection pens displayed on pedestals: Semaglutide (multi-dose weekly injection) on the left, approved for Type 2 Diabetes, Heart and Kidney Protection; Tirzepatide (single-use weekly injection) on the right, approved for Weight Loss and Sleep Apnea.

Ozempic vs Zepbound at a Glance: Full Side-by-Side Comparison

Every comparison page gives you a table. Ours includes the things that actually change your decision — not just medical specs, but the insurance logic and what you’ll really pay.

	Ozempic	Zepbound
Generic name	Semaglutide	Tirzepatide
Manufacturer	Novo Nordisk	Eli Lilly
How it works	GLP-1 receptor agonist (1 hormone)	GLP-1 + GIP receptor agonist (2 hormones)
FDA-approved for weight loss?	❌ No — off-label only	✅ Yes
FDA-approved for type 2 diabetes?	✅ Yes	❌ No (Mounjaro is the diabetes version)
FDA-labeled cardiovascular benefit?	✅ Yes — reduces major CV events in T2D + heart disease	⏳ Not yet (SURMOUNT-MMO trial ongoing)
FDA-labeled kidney benefit?	✅ Yes — reduces CKD progression in T2D + CKD	❌ No
FDA-approved for sleep apnea?	❌ No	✅ Yes (2024)
Head-to-head weight loss (SURMOUNT-5)	13.7% of body weight	20.2% of body weight — 47% more
Max weekly dose	2 mg	15 mg
Lowest cash-pay	$199/mo intro (NovoCare, first 2 fills, through 6/30/26)	$299/mo (LillyDirect, 2.5 mg, within 45-day refill)
Insurance pattern	Easier for diabetes diagnosis	Better for obesity/weight-loss diagnosis
Best for	Type 2 diabetes + cardiovascular/kidney risk	Maximum weight loss in adults with obesity

Sources: ¹SURMOUNT-5, NEJM 2025; ²Ozempic prescribing information 2025; ³Zepbound prescribing information 2026; pricing verified April 2026 from ozempic.com and zepbound.lilly.com.

Note on weight-loss numbers: SURMOUNT-5 compared tirzepatide vs semaglutide at doses up to 2.4 mg — which is Wegovy-range dosing, not Ozempic’s maximum 2 mg diabetes dose. We explain this distinction fully in the evidence section below.

How Ozempic and Zepbound Differ infographic. Ozempic (semaglutide): Targets GLP-1. Approved for: Type 2 diabetes; reducing certain cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease; reducing risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Zepbound (tirzepatide): Targets GLP-1 + GIP. Approved for: Chronic weight management in eligible adults; moderate-to-severe obstructive sleep apnea in adults with obesity. One targets GLP-1, one targets GLP-1 and GIP. Their labels and best-fit use cases are different.

Who Should Choose Which? It Comes Down to 4 Situations

Most pages tell you “talk to your doctor.” That’s true — but unhelpful when you’re trying to walk into that conversation with a clear preference. Here’s how to think about it.

Situation 1

Your main goal is losing the most weight possible

→ Choose Zepbound

Zepbound targets two appetite-regulating hormones (GLP-1 and GIP) instead of one. In SURMOUNT-5, that dual mechanism translated into 47% more weight loss than semaglutide.^¹ It’s also the only one of these two drugs that’s FDA-approved for chronic weight management.^³

If you don’t have diabetes and your primary motivation is weight loss, Zepbound is the clinically supported choice.

See If You Qualify for Zepbound on Ro →

Insurance concierge included · PA handling · Separate membership fee applies

Situation 2

You have type 2 diabetes

→ Start with Ozempic

Ozempic’s FDA label covers three things Zepbound’s does not: glycemic control in type 2 diabetes, reduction of major adverse cardiovascular events (heart attack, stroke, CV death) in adults with T2D and established heart disease, and reduction of kidney disease progression in adults with T2D and chronic kidney disease.^²

Those aren’t small differences. They’re labeled, proven benefits backed by dedicated clinical trials. Your insurance is also significantly more likely to cover Ozempic when it’s prescribed for diabetes.

Check If Your Insurance Covers Ozempic on Ro →

Free coverage check · Ro membership fee applies separately

Situation 3

You need the most affordable path

→ Compare these cash-pay options (April 2026)

Ozempic via NovoCare

$199/mo first 2 fills (0.25–0.5 mg, through 6/30/2026) · then $349/mo (0.25–1 mg) · $499/mo (2 mg)

Zepbound via LillyDirect

$299/mo (2.5 mg) · $399/mo (5 mg) · $449/mo (7.5–15 mg) — must refill within 45 days

TrumpRx program

Ozempic $199/mo · Zepbound $299/mo · Requires valid Rx · No Medicare/Medicaid

If even these are too steep, telehealth providers like MEDVi offer FDA-approved GLP-1 programs with competitive pricing structures — worth exploring if insurance isn’t an option.

Explore Affordable FDA-Approved GLP-1 Options on MEDVi →

FDA-approved medications · Streamlined telehealth process

Situation 4

You’re already on Ozempic and wondering about switching

→ Check the math before you switch

The SURMOUNT-5 data suggests you’d likely lose more weight on tirzepatide.^¹ But the insurance math matters. If your plan covers Ozempic for diabetes at a $25 copay and won’t cover Zepbound for weight loss, switching could mean going from $25/month to $299+ out of pocket.

Check Your Zepbound Coverage Before Switching — Ro →

Free insurance checker · Know the numbers before you decide

Which One Fits Your Situation? Decision framework. Ozempic may fit better if: you have type 2 diabetes; heart or kidney risk reduction is a priority; your insurance covers diabetes treatment more easily than weight-loss treatment. Zepbound may fit better if: your main goal is maximum weight loss; you want a medication approved for chronic weight management; you have obesity-related sleep apnea. Next step: Still unsure? Check coverage, budget, and your diagnosis before deciding.

How Much Weight Will You Lose? The Head-to-Head Evidence

Quick answerIn the only direct head-to-head trial (SURMOUNT-5, NEJM 2025), tirzepatide produced 20.2% vs 13.7% average weight loss over 72 weeks — 47% more relative weight loss. But the nuance matters: these used Wegovy-range semaglutide doses, not Ozempic’s diabetes doses.

SURMOUNT-5: The Only Direct Head-to-Head Comparison

SURMOUNT-5 enrolled 751 adults with obesity (BMI ≥30, or ≥27 with comorbidities) who did not have type 2 diabetes. Participants received either the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) — weekly injections for 72 weeks. Results were published in the New England Journal of Medicine in July 2025.^¹

Head-to-Head Obesity Trial Average Weight Loss infographic. Tirzepatide showed greater average weight loss than semaglutide over 72 weeks. Tirzepatide: 20.2% average body weight loss, greater average reduction in waist circumference. Semaglutide: 13.7% average body weight loss, also showed reduction in waist circumference. Trial context: adults with obesity but without diabetes.

Outcome	Tirzepatide	Semaglutide
Average weight loss	20.2% of body weight	13.7% of body weight
Average pounds lost	50.3 lbs	33.1 lbs
Lost ≥15% body weight	64.6% of participants	40.1% of participants
Lost ≥25% body weight	31.6% of participants	16.1% of participants
Waist circumference reduction	7.2 inches	5.1 inches
Stopped due to GI side effects	2.7%	5.6%

Source: Aronne et al., SURMOUNT-5, NEJM 2025.¹

Two things worth noticing. First, tirzepatide didn’t just produce slightly more weight loss — nearly twice as many people hit the 25% threshold. Second, fewer people quit tirzepatide due to stomach issues than quit semaglutide. That challenges the common assumption that “stronger drug = harder to tolerate.”

The Nuance That Matters: These Doses Are Wegovy-Range, Not Ozempic-Range

SURMOUNT-5 used semaglutide at doses up to 2.4 mg — which matches Wegovy dosing for weight loss. Ozempic’s maximum approved dose is 2 mg, and it’s approved for diabetes management, not weight loss.^²

In Ozempic’s own diabetes-focused trials (the SUSTAIN program), weight loss was a secondary outcome. Adults lost an average of approximately 7 to 14 lbs depending on the dose and comparator.^⁴

We include this detail because accuracy builds trust. You’ll find plenty of pages that slap the 13.7% number next to the word “Ozempic.” That’s not quite right. The 13.7% reflects Wegovy-range semaglutide dosing in a weight-loss trial. Your individual results at Ozempic’s diabetes doses will likely be less.

What Could Your Results Look Like?

These projections use SURMOUNT-5 trial averages for tirzepatide (20.2%) and a conservative estimate for Ozempic-range semaglutide dosing (~10%). Your individual results will vary.

Starting weight	Ozempic (~10%)	Zepbound (~20%)	Difference
200 lbs	~20 lbs → 180 lbs	~40 lbs → 160 lbs	+20 lbs
225 lbs	~23 lbs → 202 lbs	~45 lbs → 180 lbs	+22 lbs
250 lbs	~25 lbs → 225 lbs	~50 lbs → 200 lbs	+25 lbs
275 lbs	~28 lbs → 247 lbs	~55 lbs → 220 lbs	+27 lbs
300 lbs	~30 lbs → 270 lbs	~60 lbs → 240 lbs	+30 lbs

Tirzepatide figure: SURMOUNT-5 average (20.2%). Semaglutide figure: conservative ~10% estimate for Ozempic-range dosing. Combined with diet and exercise. Not a guarantee — a realistic range. If prescribed Wegovy for weight loss, semaglutide results are closer to ~14–15%.

If you weigh 250 lbs, the difference between these two medications could be roughly 25 additional pounds lost. That’s not a rounding error — that’s a different clothing size, a different energy level, and potentially a different health trajectory.

Seen the data. Ready to find out what you qualify for?

Ro pairs you with a licensed clinician, checks your insurance, and handles prior authorizations for both Ozempic and Zepbound.

See What You’re Eligible For — Check Coverage on Ro →

FDA-approved medication · Free insurance check · PA handling included

When Ozempic Is Actually the Smarter Choice

Quick answerHere’s the honest take: Zepbound is not the right choice for everyone. Ozempic carries three FDA-labeled benefits that Zepbound does not have — and they matter if your health picture is more complex than weight alone.

Blood sugar control in type 2 diabetes

Ozempic is specifically approved and dosed for T2D management, with extensive clinical data behind it. Zepbound is not approved for type 2 diabetes (Mounjaro, tirzepatide's diabetes version, is).

Cardiovascular risk reduction

Ozempic's label includes reduction of major adverse cardiovascular events (CV death, nonfatal heart attack, nonfatal stroke) in adults with T2D and established cardiovascular disease — based on the SUSTAIN 6 cardiovascular outcomes trial. Zepbound's CV outcomes trial (SURMOUNT-MMO) is ongoing.

Kidney disease protection

Based on the FLOW trial (NEJM, 2024), Ozempic reduces the risk of kidney disease progression, end-stage kidney disease, and cardiovascular death in adults with T2D and chronic kidney disease. Zepbound does not have this label.

The practical impact: If your doctor is prescribing this medication primarily for type 2 diabetes management — particularly if you have heart disease or kidney concerns — Ozempic is likely the right call. You’ll still lose weight (most people do, even at diabetes doses), and you get those additional protective benefits that could meaningfully change your long-term health outcomes.

Diabetes, Heart, or Kidney Priority? Check Ozempic Coverage on Ro →

Ozempic vs Zepbound Cost in 2026: What You’ll Actually Pay

Quick answerNobody should pay list price ($1,000+/month) for either drug. The cash-pay programs have improved significantly. Here are the verified numbers as of April 2026.

List Prices (What Almost Nobody Pays)

Ozempic list price

~$1,028/month

Almost nobody pays this

Zepbound list price

~$1,086/month

Almost nobody pays this

With Commercial Insurance

Ozempic + commercial insurance (T2D)

As low as $25/month with the Novo Nordisk savings card. Most commercial plans cover Ozempic for documented T2D — this is the most reliable path to affordable GLP-1 coverage.

Zepbound + commercial insurance (obesity)

As low as $25/month with the Eli Lilly savings card — if your plan covers it. Coverage is improving but not universal. Typically requires BMI ≥30 or ≥27 with comorbidities.

Without Insurance: Cash-Pay Programs

Program	Ozempic	Zepbound
Manufacturer direct	NovoCare: $199/mo first 2 fills (0.25 or 0.5 mg, through 6/30/26) → $349/mo (0.25–1 mg) → $499/mo (2 mg)	LillyDirect: $299/mo (2.5 mg) → $399/mo (5 mg) → $449/mo (7.5–15 mg) if refilled within 45 days. Higher outside that window.
TrumpRx	$199/month	$299/month
Ro	Available — insurance concierge included. Separate membership fee applies.	Available — insurance concierge included. Separate membership fee applies.
MEDVi	FDA-approved GLP-1 options available	FDA-approved GLP-1 options available

All pricing verified April 2026 from manufacturer savings pages. Prices may vary by dose and program terms.

Medicare: A Historic Change Is Coming

Medicare GLP-1 Bridge (July 1 – December 31, 2026)

Zepbound covered · Wegovy covered

CMS will cover Wegovy and Zepbound for weight reduction at a $50/month copay for eligible Medicare Part D beneficiaries. Requires BMI 35+, or BMI 27+ with specific clinical criteria. Prior authorization through a CMS central processor required. Does not cover Ozempic or Mounjaro for weight loss.

BALANCE Model (January 2027)

Plan-dependent

A voluntary longer-term model that participating Part D plans can opt into. May include a broader set of GLP-1 medications including Ozempic and Mounjaro, but coverage depends on whether your specific plan joins. Not guaranteed universal coverage.

If you’re on Medicare and want GLP-1 access for weight loss, the Bridge program starting in July could be your best opportunity. Talk to your doctor now about eligibility. Ozempic continues to be covered under standard Medicare Part D when prescribed for type 2 diabetes.

See Current Pricing and Check Your Coverage — Ro →

Free insurance checker · Both Ozempic and Zepbound · Membership fee applies

Does Insurance Cover Ozempic or Zepbound for Weight Loss?

Quick answerInsurance is the single biggest variable in this decision. It can turn a $1,000/month medication into a $25 copay — or block you entirely.

Ozempic for diabetes

Reliable

Most commercial plans cover it, often with prior authorization. The most reliable path to insurance-covered GLP-1 treatment.

Ozempic for weight loss

Rarely covered

Rarely covered. Not FDA-approved for weight loss. Insurers typically deny off-label weight-loss prescriptions.

Zepbound for weight loss

Inconsistent

Improving but inconsistent. Some plans cover for obesity (BMI ≥30 or ≥27 with comorbidities). Many still don't.

Zepbound for sleep apnea

Better odds

Better odds since FDA approved Zepbound for moderate-to-severe OSA in 2024.

How to Maximize Your Coverage Chances

Get a formal diagnosis documented — BMI ≥30, or ≥27 with comorbidities like hypertension, sleep apnea, or high cholesterol

Document every comorbidity — each one strengthens your prior authorization request

Have your doctor submit a prior authorization with full medical records, lab work, and documentation of medical necessity

If denied, appeal — many initial denials are overturned with supporting documentation

Consider a provider with insurance support — Ro handles prior authorizations and appeals on your behalf

Ozempic vs Zepbound Side Effects: Which Is Harder to Tolerate?

Quick answerBoth medications cause similar side effects — mostly gastrointestinal, mostly temporary. The surprise: in SURMOUNT-5, fewer people quit tirzepatide due to GI side effects (2.7%) than quit semaglutide (5.6%). Stronger for weight loss does not mean harder to tolerate.

Common side effects (both)

·Nausea — peaks in first 2–4 weeks and during dose increases
·Diarrhea
·Constipation
·Stomach pain / abdominal discomfort
·Vomiting — more common during escalation
·Fatigue
·Injection site reactions

Zepbound-specific notes

·Hair loss listed on Zepbound's label (generally from rapid weight loss)
·Injection site reactions more commonly noted on Zepbound's label
·Despite stronger weight loss, fewer GI discontinuations in SURMOUNT-5 (2.7% vs 5.6%)

Serious side effects to know about (both): Pancreatitis (rare — report severe abdominal pain immediately), gallbladder problems, kidney issues (usually from dehydration), and thyroid tumor risk (boxed warning on both). Both labels also note monitoring for diabetic retinopathy in patients with pre-existing disease.

How to Minimize Side Effects

✓

Start at the lowest dose and titrate slowly — both medications have a gradual schedule for exactly this reason

✓

Eat smaller, more frequent meals — the single most effective dietary adjustment

✓

Avoid greasy or heavy foods during the first weeks

✓

Stay hydrated — dehydration worsens GI symptoms

✓

Take your injection at the same time each week

✓

If a side effect persists, tell your provider — dose adjustments often resolve it

Want a Provider Who Adjusts Your Plan As You Go? Check Eligibility on Ro →

Licensed clinician oversight · Dose adjustment support

Can You Switch from Ozempic to Zepbound?

Quick answerYes — and many people do. It’s one of the most discussed topics in GLP-1 communities. Weight-loss plateau is the most common reason.

Common reasons people switch

Weight-loss plateau on Ozempic

After initial results, weight stabilizes despite dose increases. SURMOUNT-5 data suggests tirzepatide can restart progress.¹

Insurance or coverage changes

Plan drops Ozempic, or you're transitioning from a diabetes treatment plan to a weight-management program.

Wanting the stronger weight-loss option

Many started with Ozempic because it was prescribed first, then learned about Zepbound's clinical advantage.

How it works

Your doctor will typically restart you at a low Zepbound dose (2.5 mg) and gradually increase, even if you were on Ozempic’s max dose. This minimizes side effects as your body adjusts.

Do not take Ozempic and Zepbound at the same time. Zepbound’s prescribing information specifically states that coadministration with any GLP-1 receptor agonist is not recommended.^³

Check the math first. If your plan covers Ozempic for diabetes at $25/month, switching to Zepbound for weight loss could mean jumping to $299+ out of pocket if weight-loss medications aren’t covered. That might be worth it — but know the numbers before you decide.

Thinking About Switching? Check Your Zepbound Coverage First — Ro →

Free insurance check · Know your out-of-pocket before you switch

Wait — Are You Actually Comparing the Wrong Two Drugs?

This might be the most valuable section on this page.

If your goal is weight loss and you don’t have diabetes, your real head-to-head comparison may be Wegovy vs Zepbound, not Ozempic vs Zepbound. Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for weight loss — same active ingredient as Ozempic (semaglutide), but at higher doses and with a different label.

Your situation	Semaglutide option	Tirzepatide option
Type 2 diabetes	Ozempic ✅	Mounjaro ✅
Weight loss (no diabetes)	Wegovy ✅	Zepbound ✅
Weight loss + sleep apnea	Wegovy	Zepbound (also FDA-approved for OSA)

Why this matters for your wallet: If you don’t have diabetes and your doctor prescribes Ozempic for weight loss, your insurer will very likely deny it — that’s off-label use. Wegovy prescribed for weight loss is an on-label use, giving you a much better shot at coverage. Similarly, if you have type 2 diabetes and want the tirzepatide mechanism, your insurance comparison isn’t Zepbound — it’s Mounjaro.

Ozempic vs Zepbound Dosing: What to Expect

Quick answerBoth are once-weekly injections that start low and increase gradually. The slow ramp-up minimizes side effects and lets your body adjust. The milligrams aren’t directly comparable between the two drugs — they’re different molecules.

Ozempic dose schedule

Period	Dose
Weeks 1–4	0.25 mg/week (adjustment dose)
Weeks 5+	0.5 mg/week (first therapeutic)
If needed	1 mg/week
Maximum	2 mg/week

Zepbound dose schedule

Period	Dose
Weeks 1–4	2.5 mg/week (starting dose)
Weeks 5–8	5 mg/week
Weeks 9+	+2.5 mg every 4+ weeks as tolerated
Maximum	15 mg/week

Are Shortages Still an Issue?

The FDA has stated that both tirzepatide injection and semaglutide injection shortages are resolved as of 2025.^¹² That said, localized or intermittent supply issues can still happen — certain doses may be temporarily unavailable at specific pharmacies. Manufacturer-direct programs (LillyDirect, NovoCare) and established telehealth providers (Ro, MEDVi) tend to have the most reliable supply chains.

How We Verified This Comparison

✓

SURMOUNT-5 (Aronne et al., NEJM, 2025)

Primary evidence — the only direct head-to-head trial published as of April 2026

✓

FDA prescribing information

Ozempic (2025 revision) and Zepbound (2026 revision) — checked for all approved indications

✓

Official manufacturer pricing pages

Ozempic.com/savings and Zepbound.lilly.com/savings — verified April 3, 2026

✓

FLOW trial (NEJM, 2024)

Source for Ozempic kidney indication data

✓

CMS Medicare GLP-1 Bridge FAQs

Updated March 2026 — Medicare coverage change details

✓

JAMA Internal Medicine real-world comparison (2024)

Real-world confirmation of SURMOUNT-5 advantage in clinical practice

What this page does not claim: We don’t provide medical advice. We don’t claim either medication guarantees specific results. We include affiliate links to providers we’ve vetted — these support our work but don’t influence our analysis. If we removed every link, this page would still be worth reading.

Frequently Asked Questions: Ozempic vs Zepbound

Is Zepbound better than Ozempic for weight loss?

For most people comparing them for weight loss, yes. The SURMOUNT-5 trial showed tirzepatide produced 20.2% average body weight loss versus 13.7% for semaglutide at comparable high doses over 72 weeks. A JAMA real-world study confirmed the advantage in everyday clinical practice. However, Ozempic may be the better overall choice if you have type 2 diabetes with cardiovascular or kidney concerns.

Is Ozempic FDA-approved for weight loss?

No. Ozempic is FDA-approved for type 2 diabetes, cardiovascular risk reduction in adults with T2D and established heart disease, and kidney disease risk reduction in adults with T2D and chronic kidney disease. Weight loss with Ozempic is off-label. The FDA-approved weight-loss version of semaglutide is Wegovy.

Who should choose Ozempic instead of Zepbound?

People with type 2 diabetes — especially if heart or kidney protection is part of the picture. Ozempic has dedicated FDA-labeled indications for reducing cardiovascular events and kidney disease progression that Zepbound cannot yet claim. Insurance coverage is also significantly easier for Ozempic when prescribed for diabetes.

Can you take Ozempic and Zepbound together?

No. Zepbound's prescribing information states that coadministration with any GLP-1 receptor agonist is not recommended. If switching, your doctor will transition you from one to the other — not overlap them.

How much does Zepbound cost vs Ozempic without insurance?

List prices are similar at roughly $1,028–$1,086/month. Through manufacturer cash-pay programs: Ozempic through NovoCare starts at $199/month for the first 2 fills of starter doses (through 6/30/2026), then $349–499/month. Zepbound through LillyDirect starts at $299/month for 2.5 mg vials when refilled within 45 days.

Does insurance cover Zepbound for weight loss?

Coverage varies by plan and is improving but not universal. Ozempic is generally easier to cover for diabetes. Starting July 2026, Medicare will cover Wegovy and Zepbound for weight loss at $50/month through the GLP-1 Bridge program for eligible beneficiaries. Check your specific plan — coverage rules change frequently.

Can you switch from Ozempic to Zepbound?

Yes, with your doctor's guidance. You'll typically restart at Zepbound's lowest dose (2.5 mg) and titrate up gradually. Check insurance implications first — your out-of-pocket cost may change substantially.

What are the side effects of Zepbound vs Ozempic?

Both commonly cause nausea, diarrhea, constipation, and stomach pain — especially during the first weeks and dose escalation. In SURMOUNT-5, fewer people stopped tirzepatide due to GI side effects (2.7%) than stopped semaglutide (5.6%). Despite being stronger for weight loss, tirzepatide does not appear to be harder to tolerate.

What if I've plateaued on Ozempic?

Plateaus are common and one of the most frequent reasons people explore switching. SURMOUNT-5 data suggests tirzepatide's dual-hormone mechanism may restart weight loss progress. Talk to your provider about whether transitioning makes sense for your situation.

Will Medicare cover Ozempic or Zepbound for weight loss?

Starting July 1, 2026, the Medicare GLP-1 Bridge program will cover Wegovy and Zepbound for weight reduction at $50/month for eligible Part D enrollees (BMI 35+, or 27+ with qualifying conditions). The Bridge does not cover Ozempic for weight loss. The voluntary BALANCE model may expand coverage through participating plans starting January 2027. Ozempic remains coverable through standard Part D for type 2 diabetes.

Still Not Sure Which GLP-1 Is Right for You?

You’ve seen the data. You know the pricing. You understand which situations favor which medication. If you’re still not 100% certain — that’s completely normal. This is a meaningful health decision. Here’s what we know: the people who get the best results are the ones who actually start.

Find Your Best GLP-1 Path — Take control of your health. Your GLP-1 match is just a few steps away, personalized for your needs, goals, and lifestyle. GLP-1 Match Quiz shown on a mobile phone screen.

Take the Free 60-Second GLP-1 Matching Quiz →

Answer a few questions about your goals, insurance, and health profile. We’ll show you which path fits — no commitment required.

Or, if you already know what you want:

Check Your Eligibility for Zepbound or Ozempic on Ro →

Ro prescribes FDA-approved GLP-1 medications, pairs you with a licensed clinician, and includes an insurance concierge that handles coverage and prior authorizations. Membership fee applies separately from medication cost.

Explore FDA-Approved GLP-1 Options on MEDVi →

FDA-approved medications · Streamlined telehealth process · Competitive pricing

Related guides

Reference Notes

Affiliate disclosure: Some links on this page go to partner providers including Ro and MEDVi. We earn a commission if you use these services at no extra cost to you. This doesn’t change our analysis or editorial independence. Our recommendations are based on clinical evidence, FDA labeling, and verified pricing — not commission rates. Full disclosure →

This page is for informational and educational purposes only. It does not constitute medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.

Last verified: April 3, 2026 · By The RX Index Editorial Team

Check Zepbound or Ozempic Coverage on Ro →

Free insurance check · FDA-approved medications · PA handling

Related guides